BBIO

BridgeBio Pharma (BBIO)

About BridgeBio Pharma (BBIO)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Details

Daily high

$26.90

Daily low

$26.02

Price at open

$26.04

52 Week High

$44.32

52 Week Low

$21.62

Market cap

5.0B

Dividend yield

0.00%

Volume

4.2M

Avg. volume

2.7M

P/E ratio

-10.98

BridgeBio Pharma News